Kenvue (NYSE:KVUE) Price Target Raised to $19.00

Kenvue (NYSE:KVUE) had its price target raised by Barclays from $18.00 to $19.00 in a research report released on Friday,Benzinga reports. They currently have an equal weight rating on the stock.

Several other equities research analysts have also commented on the stock. UBS Group boosted their target price on shares of Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group raised their price objective on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Citigroup boosted their price objective on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research report on Friday, January 9th. Finally, Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the company from $23.00 to $18.00 in a report on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $19.58.

Kenvue Stock Performance

Shares of KVUE stock opened at $18.41 on Friday. The company has a market cap of $35.29 billion, a price-to-earnings ratio of 23.91, a price-to-earnings-growth ratio of 4.21 and a beta of 0.51. The stock has a 50 day simple moving average of $17.85 and a 200-day simple moving average of $17.40. Kenvue has a 12-month low of $14.02 and a 12-month high of $25.17. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. During the same period in the previous year, the business earned $0.26 earnings per share. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. On average, equities analysts forecast that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.5%. Kenvue’s payout ratio is 107.79%.

Insider Activity at Kenvue

In other news, Director Jeffrey C. Smith acquired 3,200,000 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was acquired at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.17% of the stock is currently owned by company insiders.

Institutional Trading of Kenvue

Hedge funds have recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new position in Kenvue in the 3rd quarter valued at $25,000. NBT Bank N A NY boosted its holdings in shares of Kenvue by 180.3% during the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares during the last quarter. Cornerstone Planning Group LLC grew its position in shares of Kenvue by 705.2% in the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after purchasing an additional 1,361 shares during the period. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the period. Finally, Elyxium Wealth LLC acquired a new position in Kenvue in the fourth quarter valued at $26,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.